Drug maker Lupin on Friday said it has received approval from the U.S. health regulator to market a generic medication to treat bacterial infections, in America.
The company has received approval from the U.S.FDA for Doxycycline for Injection USP, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Pfizer Inc's Vibramycin for injection, it added.
The product will be manufactured at its Nagpur facility, Lupin said.
Doxycycline for Injection USP is indicated to reduce the development of drug-resistant bacteria.
As per the IQVIA MAT January 2024 data, Doxycycline for Injection USP had estimated annual sales of $47 million in the U.S. market.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
